FMC-R regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: FCMR regimen; FCM-R regimen; FMC-R regimen; R-FCM regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone regimen
Overview
FMC-R regimen refers to a regimen consisting of fludarabine, mitoxantrone, cyclophosphamide and rituximab, used in the treatment of resistant or relapsed chronic lymphocytic leukaemia.[1]
Regimen
FFludarabine
MMitoxantrone
CCyclophosphamide
RRituximab
Indications
- Indolent non-Hodgkin’s lymphoma and relapsed or refractory mantle cell lymphoma.[2]
- CLL[3]
References
- ↑ Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B; et al. (2004). “The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group”. Blood. 104 (10): 3064–71. doi:10.1182/blood-2004-04-1323. PMID 15284112.
- ↑ “NCI Thesaurus”.
- ↑ Faderl S, Wierda W, O’Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). “Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years”. Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH